In this article, we deep dive into the 5 stocks defying the market slump. For a deeper discussion and an extended list, please see 10 Stocks Making Investors Richer.
Photo by Mizuno K on Pexels
5. Moderna Inc. (NASDAQ:MRNA)
Moderna extended its winning streak to a fifth consecutive day on Wednesday, climbing 11.55 percent to end at $61.80 apiece, as investors loaded their portfolios ahead of its Investor Day.
In a notice, Moderna Inc. (NASDAQ:MRNA) said that it will host an Investor Event at 9 AM ET next Thursday, June 25.
The company said that it is set to discuss and feature research and early development programs, highlighting how its mRNA platform, together with advances in AI and robotics, is accelerating innovation and creating opportunities to expand into new therapeutic areas.
In other news, Moderna Inc. (NASDAQ:MRNA) on Tuesday said that it is anticipating the launch of three vaccines for flu plus COVID, seasonal flu, and norovirus over the next two years.
At the same time, it is expecting important clinical milestones this year, including potential pivotal data readouts for its investigational individualized neoantigen therapy (Intismeran autogene) and a therapeutic for the rare genetic disease propionic acidemia, which could support the possible launch of its first oncology and rare disease products.
In other news, Moderna Inc. (NASDAQ:MRNA) appointed Ester Banque as its new chief commercial officer, effective on Monday, June 15. She is tasked to focus on continuing to build out the company’s global commercial organization, leading execution across product launches, and expanding presence in new markets.
4. Eos Energy Enterprises Inc. (NASDAQ:EOSE)
Eos Energy extended its winning streak to a third consecutive day on Wednesday, surging 11.60 percent to end at $7.60 apiece after partnering with a German battery maker to support its expansion into three European countries.
In a statement, the company said that it joined forces with CAPAC Energy (formerly Nala Energy GmbH) for the establishment of a 750 MWh energy capacity across Germany, Australia, and Switzerland, with the potential to scale up to 2 GWh, over the next five years.
Eos Energy Enterprises Inc. (NASDAQ:EOSE) also tapped CAPAC Energy for the exclusive distribution of its technologies in the said countries.
“Germany is rapidly emerging as a critical market for long-duration energy storage. The ongoing phase-out of coal-fired generation, ambitious renewable energy targets, continued solar capacity growth, and increasing grid complexity are driving demand for flexible, multi-hour storage solutions capable of balancing supply and demand. Recent regulatory developments, including updated building code privileges for grid-scale batteries, co-location reforms, and a capacity market mechanism expected to launch in 2027, are further enhancing the long-term outlook for storage deployment in the German market,” Eos Energy Enterprises Inc. (NASDAQ:EOSE) said.
CAPAC Energy is currently advancing the construction of its first Eos projects in Germany with commercial operations targeted for late 2026.
3. Biohaven Ltd. (NYSE:BHVN)
Biohaven soared by 12.66 percent on Wednesday to close at $13.62 apiece, as investors positioned their portfolios ahead of the initiation of two pivotal studies for its endometrial and urothelial cancer treatment candidates by the end of the month.
Based on its key milestone calendar, Biohaven Ltd. (NYSE:BHVN) is set to initiate clinical studies for its BHV-1510 for advanced or metastatic epithelial tumors, as well as the BHV-1530 for urothelial cancer and other tumors, in the first half of the year.
Apart from the said pipelines, Biohaven Ltd. (NYSE:BHVN) is also planning to initiate pivotal studies for BHV-1400 for the treatment of IgAN, or Berger disease, as well as BHV-1300 for Graves ‘ disease, in the middle of the year.
Biohaven Ltd. (NYSE:BHVN) is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology.
In the first quarter of the year, it was able to slash its net losses by 41 percent to $130.5 million from $221.7 million in the same period last year. It has yet to generate revenues as of the period.
2. Rackspace Technology Inc. (NASDAQ:RXT)
Rackspace Technology soared to a four-year high on Wednesday, extending a winning streak to a third consecutive day, as investors gobbled up shares after clinching a new 30 MW cloud computing deal with Advanced Micro Devices (AMD).
In intra-day trading, Rackspace Technology Inc. (NASDAQ:RXT) soared to a four-year high of $8.60 before paring gains to finish the session just up by 21.26 percent at $7.53.
In a statement on the same day, the two firms said that they joined forces for the phased deployment of an initial 30 MW footprint dedicated to AMD-based compute across Rackspace Technology Inc.’s (NASDAQ:RXT) global data centers beginning late this year through 2028.
The deployment followed a memorandum of understanding inked last month, which establishes AMD as a strategic technology partner at the silicon layer of Rackspace’s governed AI stack.
The full deployment would support regulated enterprise workloads, including healthcare providers who have expressed early interest in accelerated compute for clinical AI and inference at scale.
Both firms expect to dedicate sales and marketing resources to identify and engage enterprise customers for AMD compute-powered infrastructure, and with each party jointly developing and pursuing customer opportunities across regulated industries.
“Enterprises in regulated industries need AI infrastructure that is governed from the ground up, with one operator accountable for business outcomes, not a collection of vendors each owning a piece,” Rackspace Technology Inc. (NASDAQ:RXT) CEO Gajen Kandiah.
“This collaboration combines the right compute with the right operating model and delivers something the market hasn’t offered before: a governed AI stack with one accountable partner from silicon to outcomes.”
1. UniQure NV (NASDAQ:QURE)
UniQure skyrocketed by 78.44 percent on Wednesday to finish at $48.16 apiece as investors gobbled up shares after the Food and Drug Administration (FDA) approved the analyses from its AMT-130 clinical study, paving the way for the submission of a biologics license application (BLA).
In an updated report, UniQure NV (NASDAQ:QURE) said that the FDA officially accepted data analysis from the first phase of the clinical trial, walking back its earlier requirement to submit additional data.
However, the agency is requiring an alignment meeting with the listed firm to discuss a confirmatory study design before the BLA, including consideration of concurrent control on standard-of-care therapy instead of a sham procedure.
UniQure NV (NASDAQ:QURE) intends to submit the BLA in the third quarter of the year.
“The FDA has agreed that our current clinical data can support a near-term BLA submission and has committed to working expeditiously with us to align on the design of the required confirmatory study. The consistency and strength of the clinical data generated to date give us great confidence in the product’s potential to make a meaningful difference for patients. We remain focused on bringing AMT-130 to patients and families as quickly and responsibly as possible in the US and globally,” UniQure NV (NASDAQ:QURE) CEO Matt Kapusta said.
AMT-130 has been granted a Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA—the first one to be designated for Huntington’s disease. It also secured a breakthrough therapy and fast-track designation.
While we acknowledge the potential of QURE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than QURE and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge fund investor letters by entering your email below.
